New Four-Target antibody enters human testing for Tough-to-Treat cancers
NCT ID NCT07416695
Summary
This is the first study in people to test a new experimental drug called HLX3901 for patients with advanced small cell lung cancer or neuroendocrine carcinoma that has worsened after standard treatments. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it might help shrink tumors. The study will enroll about 138 adults whose cancer has progressed despite prior platinum-based therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Chest Hospital
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.